Effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in HIV late presentersDiana Corona‐Mata, Antonio Rivero, Ignacio Valero et al.|International Journal of Antimicrobial Agents|2023Cited by 15
Long-term effectiveness and tolerability of dolutegravir/lamivudine in treatment-naive people with HIV: an analysis of a multicentre cohort at 96 weeksInés Suárez‐García, María Remedios Alemán Valls, Roberto Muga et al.|Journal of Antimicrobial Chemotherapy|2024Cited by 4
Hodgkin and non‐Hodgkin lymphomas in the post‐antiretroviral therapy era according to <scp>HIV</scp> virological suppressionTeresa Aldámiz‐Echevarria, CoRIS Cohort, Francisco Tejerina et al.|HIV Medicine|2026Cited by 1
Beyond Surveillance Mutations: Long-Term Trends and Clinical Relevance of Transmitted HIV Drug Resistance in Spain (2007–2023)Paloma Muñoz Báez, Féderico García, Marta Illescas López et al.|Open Forum Infectious Diseases|2026Cited by 0